MIST - Wutah pendapatan taun lumaku milestonepharma.com

Tandha merek Milestone Pharmaceuticals Inc (MIST)

The TTM revenue growth rate for Milestone Pharmaceuticals (MIST), which stands at 0.00, complements the profile of this cardiology biopharmaceutical company characterized by an academic culture and a strong R&D team. The development of tachycardia treatments here relies on automated synthesis and physician expertise, while the strategy is based on the support of a commercial partner to secure regulatory approvals.

MIST - Wutah dodolan YoY sajrone rolas wulan kepungkur milestonepharma.com ing rentang 11.02.2024 - 17.11.2026

milestonepharma.com (MIST) - rincian metrik lan laporan keuangan

- rega saham lan prakiraan rega para ahli:
Analisis kabeh metrik perusahaan:Milestone Pharmaceuticals Inc
Produk merek Milestone Pharmaceuticals

Demand for Milestone Pharmaceuticals (MIST) cardiology drugs is independent of macro cycles, although the cost of funding development remains sensitive to the capital market. The relative change in rolling year revenue compared to the same period last year measures business growth rates, allowing investors to filter out short-term noise and assess the company's actual resilience to shocks by analyzing the trend on this chart.